Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society

Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society

PR Newswire

LONDON, Feb. 18, 2021

Partnerships reinforce Hikma's commitment to supporting charitable organisations addressing unmet healthcare needs for underserved patients

LONDON, Feb. 18, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it donated over $4 million USD in medicines in 2020 through its global medicine donation program, continuing its long-running commitment to supporting charities that address health issues in underserved communities around the world.

Hikma also announces it has extended and increased donation agreements with its existing partners, Dispensary of HopeDirect Relief and the National Children's Cancer Society. Additionally, Hikma has established new partnerships with Americares, a global health-focused relief and development organisation that provides medicine, medical supplies and health programs to people affected by poverty or disaster; as well as Brother's Brother Foundation, which provides essential healthcare, infrastructure, disaster response and education resources to people in 42 countries.

"Hikma is committed to bringing better health to patients and communities around the world," said Hana Ramadan, Vice President, Corporate Social Responsibility. "With the help of our partners throughout the past year, we have increased our medicine donations to low-income groups, displaced peoples and the uninsured -- all of whom faced increased challenges due to the COVID-19 pandemic. By expanding our partnerships with these vital charitable organisations, we will be able to provide broader support for those most in need during this critical time."

In 2020, Hikma donated $4.06 million in medicine, compared with $3.1 million in 2019. This included $1.1 million worth of medicines provided to the Lebanese Ministry of Health immediately following the massive explosion in Beirut this past August. The company also offered assistance to those impacted by the extreme floods that took place in Sudan in September 2020 by supporting 26,000 families with essential medicines while providing 5,200 families with insecticides to protect against the spread of mosquito-borne diseases. In the US, Hikma provided more than 600,000 meals through its employee matching donation campaign to pantries and food banks serving communities in the company's New Jersey and Ohio office locations.

Hikma US has formalised relationships and established new partnerships with the following NGOs, including:

"With Hikma's help, we are able to distribute lifesaving cancer drugs to paediatric oncology facilities we partner with. We're thankful for Hikma's compassionate giving," explained Elizabeth Payne, Director, Michele Hertlein Global Outreach Program for the National Children's Cancer Society.

"Our partnership with Hikma expands the donated inventory of primary care chronic illness and acute illness medications to serve our nation's lowest income and uninsured friends, family and neighbors," said Christopher Palombo, Chief Executive Officer, Dispensary of Hope. "We are especially appreciative of Hikma's continued support."

Inquiries        

Hikma Pharmaceuticals PLC          

Steve Weiss

US Communications and Public Affairs 

+1 732 788 8279

uscommunications@hikma.com

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Photo - https://mma.prnewswire.com/media/1165956/Hikma_Primary_Coral_Logo.jpg

 

Voltar noticias em Inglês